Company:  RUBIUS THERAPEUTICS, INC. (RUBY)
Form Type:  4
Filing Date:  6/19/2019 
CIK:  0001709401 
Address:  399 BINNEY STREET, SUITE 300 
City, State, Zip:  CAMBRIDGE, Massachusetts 02139 
Telephone:  617-679-9600 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$14.14  
Change: 
-0.51 (-3.48%)  
Trade Time: 
01:13 PM EST  
Market Cap: 
$1.13B
Trade RUBY now with

© 2019  
Description of Business
We are developing a new class of cellular medicines, Red Cell Therapeutics, or RCTs. Based on our vision that human red blood cells are the foundation of the next significant innovation in medicine, we have designed a proprietary platform to genetically engineer and culture RCTs that are selective, potent and ready­to­use cellular therapies. We believe that our RCTs will provide life­changing or life­saving benefits for patients with severe diseases across multiple therapeutic areas. We have generated hundreds of RCTs using our RED PLATFORM®, a highly versatile and proprietary cellular therapy platform. We are utilizing our universal engineering and manufacturing processes to advance a broad pipeline of RCT product candidates into clinical trials in rare diseases, cancer and autoimmune diseases. Common design and manufacturing elements of our RCTs should enable us to achieve significant advantages in product development.
Register and access this filing in:     
  FORM 4
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    EXPLANATIONS AND REMARKS
    REPORTING OWNERS
    SIGNATURES